Identity
- Security key
- 17955
- Ticker
- LCTX
- Type
- CS — Common Stock
- Exchange
- NYSE American, LLC(XASE)
- Venue group
- NYSE
- Operating MIC
- XNYS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 1992-03-05
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- LCTX
Detail
Enriched 2026-08-14 20:47
- Market cap
- $278,198,210.4
- Shares outstanding (class)
- 252,907,464
- Shares outstanding (weighted)
- 252,907,464
- SIC
- 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
- Employees
- 77
- Location
- CARLSBAD, CA
- Homepage
- https://www.lineagecell.com
- Description
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.